Self-Host
Tools / Inside Trading Tracker
Inside Trading Tracker
Track insider trading activity at publicly traded companies to understand how executives are trading their shares.
Acurx Pharmaceuticals Inc. (ACXP) Insider Trading Activity
Healthcare • Biotechnology • 4 employees
Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections. It also develops ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumonia. Acurx Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Staten Island, New York.
Total Value
$170,000.30
Total Shares
167,488
Average Trade Value
$28,333.38
Most Active Insider
Luci David P
Total Activity: $50,000
Largest Single Transaction
$50,000
by Luci David P on Jan 6, 2025
30-Day Activity
0 Transactions
Volume: 0 shares
Value: $0
|
Name
|
Position
|
Date
|
Shares
|
Value
|
Holdings
|
Type
|
|---|---|---|---|---|---|---|
|
Director
|
Jan 6, 2025 | 9,852 | $10,000 | 22,352 (+44.1%) | Purchase | |
|
Director
|
Jan 6, 2025 | 9,852 | $10,000 | 21,776 (+45.2%) | Purchase | |
|
President and CEO
Director, Officer, 10% Owner
|
Jan 6, 2025 | 49,261 | $50,000 | 1,097,458 (+4.5%) | Purchase | |
|
Director, 10% Owner
|
Jan 6, 2025 | 49,261 | $50,000 | 1,010,196 (+4.9%) | Purchase | |
|
Director
|
Jan 6, 2025 | 24,631 | $25,000 | 137,183 (+18.0%) | Purchase | |
|
Director
|
Jan 6, 2025 | 24,631 | $25,000 | 27,708 (+88.9%) | Purchase |